Clostridium difficile associated risk of death score (CARDS): A novel severity score to predict mortality among hospitalised patients with C. difficile infection

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 6, 2016, Pages 725-733

  Kassam, Z ^a,b   Cribb Fabersunne, C ^c,d   Smith, M B ^a,b   Alm, E J ^a   Kaplan, G G ^e   Nguyen, G C ^f   Ananthakrishnan, A N ^c,g  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b OpenBiome   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLOSTRIDIUM DIFFICILE ASSOCIATED RISK OF DEATH SCORE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9-CM; INFLAMMATORY BOWEL DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VALIDATION PROCESS; YOUNG ADULT; ADOLESCENT; AGE; CLOSTRIDIUM INFECTION; COMORBIDITY; HEALTH STATUS INDICATOR; MULTIVARIATE ANALYSIS; ODDS RATIO; PEPTOCLOSTRIDIUM DIFFICILE; SOCIOECONOMICS; STATISTICAL MODEL; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMORBIDITY; FEMALE; HEALTH STATUS INDICATORS; HOSPITALIZATION; HUMANS; INPATIENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84958568699     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13546     Document Type: Article

References (42)

1. Magill SS, Edwards JR, Bamberg W, et al,. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370: 1198-208.
2. Zilberberg M, Shorr A, Kollef M,. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.
3. Gravel D, Miller M, Simor A, et al,. Health care associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009; 48: 568-76.
4. Bauer MP, Notermans DW, van Benthem BHB, et al,. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
5. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S,. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
6. Simango C, Uladi S,. Detection of Clostridium difficile diarrhoea in Harare, Zimbabwe. Trans R Soc Trop Med Hyg 2014; 108: 354-7.
7. Collins D, Hawkey PM, Riley TV,. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control 2013; 2: 21.
8. McGlone S, Bailey R, Zimmer S,. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18: 282-9.
9. Dubberke E, Olsen M,. Burden of clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (Suppl. 2): S88-92.
10. Vonberg R, Reichardt C, Behnke M,. Cost of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70: 15-20.
11. Surawicz CM, Brandt LJ, Binion DG, et al,. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98.
12. Fischer M, Cook G, Rogers N, et al,. Rescue therapy with fecal microbiota transplantation in hospitalized patients with severe and severe-complicated Clostridium difficile infection. American College of Gastroenterology Annual Scientific Meeting, 2014 October 17-22; Philadelphia, PA: P935.
13. Zar F, Bakkanagari SR, Moorthi KMLST, Bakkanagari MB,. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
14. Hu MY, Katchar K, Kyne L, et al,. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136: 1206-14.
15. Abou Chakra CN, Pepin J, Valiquette L,. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS ONE 2012; 7: e30258.
16. Nguyen GC, Kaplan GG, Harris ML, Brant SR,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
17. Ananthakrishnan AN, McGinley EL, Binion DG,. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10.
18. Negrón ME, Barkema HW, Rioux K, et al,. Clostridium difficile infection worsens the prognosis of ulcerative colitis. Can J Gastroenterol Hepatol 2014; 28: 373-80.
19. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K,. A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol 2010; 105: 1799-807.
20. Molodecky NA, Panaccione R, Ghosh S, Barkema HW, Kaplan GG,. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 1792-9.
21. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG,. Temporal trends in disease outcomes related to clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 976-83.
22. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality.
23. Dubberke ER, Reske KA, McDonald LC, Fraser VJ,. ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis 2006; 12: 1576-9.
24. Dubberke ER, Butler AM, Nyazee HA, et al,. The impact of ICD-9-CM code rank order on the estimated prevelance of Clostridium difficile infections. Clin Infect Dis 2011; 53: 20-5.
25. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
26. Quan H, Sundararajan V, Halfon P, Fong A,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 Administrative Data. Med Care 2005; 43: 1130-9.
27. Abou Chakra CN, Pepin J, Sirard S, Valiquette L,. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE 2014; 9: e107420.
28. Inns T, Gorton R, Berrington A, et al,. Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect 2013; 84: 235-41.
29. Lamontagne F, Labbé A-C, Haeck O, et al,. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267-72.
30. Stewart DB, Hollenbeak CS,. Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. J Gastrointest Surg 2011; 15: 1548-55.
31. Kenneally C, Rosini JM, Skrupky LP, et al,. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007; 132: 418-24.
32. Kim ES, Kim YJ, Park CW, et al,. Response failure to the treatment of Clostridium difficile infection and its impact on 30-day mortality. Hepatogastroenterology 2013; 60: 543-8.
33. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al,. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2009; 2010: 106-13.
34. Shakov R, Salazar RS, Kagunye SK, Baddoura WJ, DeBari V,. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 2011; 39: 194-8.
35. Viladomiu M, Hontecillas R, Pedragosa M, et al,. Modeling the role of peroxisome proliferator-activated receptor and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS ONE 2012; 7: e47525.
36. Park SW, Choi AR, Lee HJ, et al,. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalized patients. Aliment Pharmacol Ther 2013; 38: 619-27.
37. Honda H, Yamazaki A, Sato Y, Dubberke ER,. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe 2014; 25: 5-10.
38. Murthy S, Steinhart H, Tinmouth J, et al,. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 1032-9.
39. Ananthakrishnan A, Guzman-Perez R, Gainer V, et al,. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 789-95.
40. Rampton D, Shanahan F,. Increased health burden associated with Clostridium difficile diarrhea in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 394-5.
41. Goodhand J, Alazawi W, Rampton D, et al,. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 428-41.
42. Khanna S, Pardi D, Aronson S, et al,. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012; 35: 613-8.